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Performing non-invasive prenatal testing (NIPT) on a pregnant woman with a 
chromosomally abnormal neoplasm may incidentally lead to the diagnosis of cancer due to the 
coexistence of circulating tumor and placental DNA. Published information regarding NIPT’s 
accuracy for neoplasm screening is limited, and guidance for patient management is currently 
lacking. This challenges clinicians’ ability to counsel patients regarding the implications of 
these results, which often is the responsibility of a genetic counselor. Over three hundred 
board-eligible/certified genetic counselors were surveyed regarding their awareness, 
preferences, and attitudes towards NIPT’s ability to indicate maternal neoplasms. Despite 95% 
of this cohort being aware of this possibility and 77% reporting that they would disclose these 
results if indicated, only 29% routinely communicate this possibility to their patients in a pre-
test setting. Management recommendations that were made by counselors were highly variable, 
and over half stated that they would feel uncomfortable or very uncomfortable counseling a 
patient with these results. While less than half of counselors believed that the current benefits 
of NIPT’s neoplasm screening ability outweigh its potential harms, 80% recognized it would be 
beneficial in the future. A vast majority of counselors in this cohort felt institutional or national 
guidelines were needed regarding the management of patients with NIPT results indicating 
maternal neoplasms.  
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INTRODUCTION  
Cell-free DNA (cfDNA) was first identified in 1947 as fragments of nucleic acids 
circulating in the blood of healthy individuals [1]. Since this initial discovery, circulating 
cfDNA has been found to originate from two additional sources:  tumor cells of cancer patients 
[2], and placental cells of pregnant women [3]. These landmark discoveries have become the 
basis of various diagnostic and screening technologies for both the fields of oncology and 
obstetrics.  
Cell-free DNA is found in the plasma of cancer patients in higher quantities compared 
to individuals without cancer, the concentration of which has been shown to inversely correlate 
with prognosis and decrease in response to successful treatment [2]. These cfDNA fragments 
are believed to originate from the cancer cells of a tumor and represent the genetic makeup of 
the malignancy, which often has genetic mutations or aberrant chromosome complements [4, 
5]. Circulating tumor DNA (ctDNA) has been the object of interest for cancer research and 
clinical test developers, as it has been proposed that specific ctDNA biomarkers may be 
identified for tumors that cannot be directly or routinely biopsied. Analysis of ctDNA, also 
referred to as a “liquid biopsy,” may be used to eliminate the need for invasive, painful, and 
costly procedures, and can be used to gauge tumor evolution and the development of resistance 
to therapy over time [4]. A 2014 study by Bettegowda et al. [6] found detectable levels of 
ctDNA in patients with metastatic and localized cancers of all stages, as well as in cases where 
cancer had not yet been detected with standard imaging, indicating a possible mechanism of 
early cancer detection. In their blinded study, Bettegowda et al. attempted to establish the 
sensitivity and specificity of the “liquid biopsy” by analyzing KRAS mutations in primary 
tumors of 206 metastatic colorectal cancer patients compared against KRAS mutations 
identified in the patient’s plasma, which yielded a sensitivity of 87.2% and a specificity of 
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99.2%. While clinical laboratories have already begun to offer “liquid biopsies” as a screening 
method to patients at risk for cancer [7], the sensitivity and specificity of ctDNA for early 
cancer detection remains largely undefined. Even if this noninvasive method is proven to be 
accurate, it does not yet directly indicate from where in the body the ctDNA is originating. 
Additionally, a biopsy of the primary tumor is still needed in order to determine if it is 
malignant or benign in nature, and to assess its degree of potential metastasis [6].   
Similarly, aneuploidy screening through Noninvasive Prenatal Testing (NIPT) analyzes 
circulating cfDNA from placental cells that are found at an average concentration of 
approximately 10% in maternal serum during pregnancy [8]. NIPT avoids the risk of 
miscarriage associated with prenatal diagnostic procedures and is a highly sensitive screen for 
specific chromosome conditions [9]. A meta-analysis by Gil et al. [10] examined 37 relevant 
studies to assess the performance of NIPT in screening for aneuploidies. The study reported the 
sensitivity to be greater than 99% for trisomy 21, 96% for trisomy 18, and 91% for trisomy 13 
with false positive rates of < 0.1%, 0.13%, and 0.13%, respectively. Known explanations for 
false positive results, or results discordant between NIPT and fetal karyotype, include statistical 
error, vanishing twin/co-twin demise, placental, fetal, and/or maternal mosaicism, undiagnosed 
maternal aneuploidy, copy number variants (CNVs), and abnormal chromosome compliment 
relating to maternal neoplasms [9, 11].  
Malignant tumors are found in about 1 in 1000 pregnant women, and benign neoplasms 
of many types, such as uterine leiomyomas, are also observed [12]. The most common cancers 
diagnosed during pregnancy are associated with those found in women of reproductive age—
breast and cervical cancer, leukemia, and lymphoma make up over 75% of reported cases [12]. 
The massively parallel shotgun sequencing (MPSS) technology utilized by some NIPT 
companies is able to assess genomic gains and losses across several chromosomes but cannot 
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make the distinction between cell-free fragments originating from different tissue sources. 
Therefore, since many malignancies are chromosomally unstable [5], the coexistence of 
circulating tumor cfDNA and placental cfDNA may incidentally lead to abnormal NIPT results 
that raise a suspicion for cancer in pregnant women who have NIPT performed for aneuploidy 
screening, as the results generated in these scenarios (monosomies or multiple aneuploidies) are 
often not compatible with life or reflect fetal findings [13-15]. 
Published information regarding NIPT’s neoplasm screening ability, intentional or 
incidental, is limited. Osborne et al. published the first case of maternal cancer that was 
diagnosed following discordant NIPT results in 2013.  The patient’s NIPT results were positive 
for both trisomy 13 and monosomy 18, and were confirmed on repeat NIPT samples at various 
points throughout the pregnancy. However, fetal anatomy, karyotype, and placental biopsy 
were normal. Following delivery, the patient experienced significant pelvic pain and was 
diagnosed with high-grade neuroendocrine sarcoma, with 80% of the examined cells 
demonstrating the previously observed aneuploidies [16]. Subsequently, two NIPT laboratories 
presented abstracts that reported cases of maternal cancers incidentally indicated by NIPT at 
the 2015 ACMG Annual Clinical Genetics Meeting [17, 18]. One report described two cases of 
multiple genomic gains or losses, one of which led to a diagnosis of invasive grade 2 breast 
cancer. A malignancy was not found in the other patient [17]. The second abstract reported 
seven confirmed, separate cases of maternal malignancy out of 37 NIPT results that detected 
multiple aneuploidies [18]. Bianchi et al. (2015) published a retrospective study of pregnant 
women who had an abnormal NIPT result involving chromosomes 21, 18, 13, X, and Y, and 
were subsequently diagnosed with cancer. This study included the previously described cases. 
This report found that out of 125,426 NIPT tests, 3,757 were abnormal for one or more 
aneuploidies. Out of this group, 10 women were reported to have been diagnosed with cancer 
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following their prenatal testing. Seven of these 10 cases screened positive for multiple 
aneuploidies. Diagnoses included lymphoma, leukemia, colorectal, anal, and neuroendocrine 
cancers. Upon further inspection of these cases, chromosomal aberrations were found spanning 
the entire genome. Even though follow-up for both normal and abnormal results was 
significantly limited, the risk for cancer when multiple aneuploidies were detected and fetal 
karyotype was normal was estimated to be 20 – 44% [19]. Later, Snyder et al. (2016) sought to 
determine the etiology of monosomy or multiple aneuploidies by conducting a retrospective 
analysis of patient follow-up and concluded that there are multiple causes for these results, 
either maternal, fetal, and placental in nature [20]. Uterine leiomyomas (fibroids) with an 
abnormal chromosome compliment have also been reported and can confound NIPT results 
[21, 22]. Given that 40-60% of women are reported to have uterine fibroids by age 35 [23], this 
is yet another factor to consider in the face of abnormal NIPT results.  
Ethical concerns as well as associated practical and legal considerations raised by 
incidental findings are not unique to NIPT. However, with respect to NIPT results indicative of 
maternal neoplasms, it is not clear what, if any, follow-up clinical evaluation is appropriate and 
little direction is available to help guide management and counseling. Yet, as of March 2016, 
laboratories performing NIPT via MPSS are either reporting results concerning for maternal 
neoplasm verbally to the ordering provider without documentation of these results on their 
reports, or are reporting results as multiple fetal aneuploidies that cannot feasibly reflect fetal 
findings. Recommendations have been proposed that pre-test NIPT counseling should include a 
statement about the possibility of incidental findings, whether they be maternal or fetal in 
nature [24], yet recommendations regarding post-test counseling and work-up in cases 
indicative of maternal malignancy are lacking and many clinicians, including genetic 
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counselors, may not be adequately equipped to counsel patients about these implications in the 
post-test setting.  
While results indicative of maternal malignancies are still rarely encountered, the 
number of women being tested via NIPT has increased with the expansion of its use from 
“high-risk populations” – women at an increased risk for a fetus with aneuploidy – to the 
general population, meaning the number of incidental findings is likely to increase as more 
women undergo NIPT. 
Prenatal or laboratory genetic counselors are often the ones involved in communicating 
NIPT results to patients or providers, particularly when they are abnormal. However, genetic 
counselors of all specialties may have a role in the management of NIPT results indicative of 
maternal neoplasms. Prenatal genetic counselors are often responsible for NIPT pre-test 
counseling, or are consulted to counsel patients post-test when abnormal NIPT results arise. 
Pediatric genetic counselors may aid in facilitating confirmatory testing of the baby at birth, 
and cancer genetic counselors may be sent referrals when ordering physicians are told by lab 
directors or lab genetic counselors that results may have a malignant etiology. Genetic 
counselors are known to specialize in communicating this information to patients and making 
appropriate recommendations for care. This study thus aims to assess genetic counselors’ 
awareness of NIPT’s ability to detect maternal neoplasms, how this may or may not affect pre-
test NIPT counseling, how counselors prefer for non-validated incidental findings of maternal 
neoplasms to be reported and managed, and their attitudes regarding NIPT’s neoplasm 
screening ability.  
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METHODS 
Participants for this study were recruited via the National Society of Genetic Counselors 
(NSGC) and included English-speaking board-eligible or board-certified genetic counselors of 
all specialties. Members who agreed to participate were asked to complete an anonymous 
online survey after providing informed consent. The survey was split into two arms based on 
the participant’s specialty of practice. Genetic counselors who indicated that they practiced in 
the prenatal setting, either exclusively or in combination with other specialties, completed the 
Prenatal Arm. Genetic counselors who indicated that they practiced in any other combination of 
specialties that did not include prenatal genetic counseling completed the Non-Prenatal Arm. 
The Prenatal Arm consisted of six sections with multiple choice questions and the opportunity 
to provide additional comments. The Non-Prenatal Arm was identical to the Prenatal Arm with 
the exception of the sections aimed at analyzing prenatal genetic counselors’ pre-test 
counseling strategies for NIPT (see appendix for survey questions). The survey was uniquely 
developed for the purpose of this study, and thus did not utilize any formal validated measures. 
Participants were incentivized to complete the study with the opportunity to win one of two 
available gift cards by providing email addresses that were not linked to their survey. 
Responses were collected for a one-month period between September and October of 2015. 
Study data were collected and managed using REDCap electronic data capture tools hosted at 
The University of Texas Health Science Center at Houston [25].  REDCap (Research 
Electronic Data Capture) is a secure, web-based application designed to support data capture 
for research studies. STATA statistical software was used to analyze data. The study was 
approved by the institutional review board at the University of Texas Health Science Center 
(HSC-MS-15-0442). 
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Statistical Analysis 
Statistically significant relationships were determined after analyzing comparison 
groups either with Pearson 2 or Fisher’s exact test. Comparison groups primarily focused on 
those practicing within particular specialties, and those who have had personal experience 
counseling about NIPT’s ability to indicate maternal neoplasms. A p-value of < 0.05 was 
considered significant.  
RESULTS 
Demographics 
A total of 367 participants responded to the survey, representing a response rate of 
approximately 13% of the NSGC membership at the time the survey was distributed. Twenty 
four participants were excluded from the study due to incomplete survey responses, leaving a 
final sample size of 343, for which 168 (49%) completed the Prenatal Arm, and 175 (51%) 
completed the Non-Prenatal Arm. The specialties of the 175 participants in the Non-Prenatal 
Arm included cancer, lab/industry, pediatrics/medical genetics, and a range of sub-specialties 
such as neurology, cardiology, pharmacogenetics, and psychiatric genetics.  
The majority of participants indicated that they had 5 years or less of total experience 
practicing as a genetic counselor (59.8%, 205/343), as well as within their current specialty 
(69.4%, 238/343). The most common place of practice was a university medical center (42.3%, 
145/343) or private hospital/medical facility (24.8%, 85/343). Genetic counselors were 
ascertained from across the country, with a majority of participants practicing in the Midwest 
(27.4%, 94/343). Eighty-seven percent of genetic counselors (298/343) reported that they were 
currently seeing patients, and 60% (206/343) indicated that they were currently discussing 
NIPT with either patients or providers. In order to assess for external validity, demographic 
8 
 
information of the dataset was compared against the 2014 National Society of Genetic 
Counselors Professional Status Survey (PSS); the sample population was found to be 
appropriately representative. Additionally, there were no statistically significant differences for 
any factors between the Prenatal and Other Arms (p > 0.05). A complete list of participant 
characteristics are described in Table 1. 
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Awareness 
As seen in Table 2, a majority of genetic counselors surveyed (95%, 326/343) reported 
they were previously aware of NIPT’s ability to indicate maternal neoplasms, with most having 
first learned of it through a professional conference, peer-reviewed journal, or discussion 
forum. Thirty (20 Prenatal Arm, 10 Non-Prenatal Arm) reported that they first learned about 
this possibility by encountering this case in their own personal experience. 
 
Table 1      Participant demographics (n = 343) 
Variable n % 
Total Years Experience 
0 – 5 years 
6 – 10 years  
11 – 15 years 
16 – 20 years 
> 20 years 
 
205 
58 
36 
18 
26 
 
59.8 
16.9 
10.5 
5.3 
7.6 
Total Years Experience in specialty 
0 – 5 years 
6 – 10 years 
11 – 15 years 
16 – 20 years 
> 20 years 
 
238 
45 
30 
12 
18 
 
69.4 
13.1 
8.8 
3.5 
5.3 
Institution Type 
University medical center 
Private hospital/medical facility 
Public hospital/medical facility 
Physician’s private practice 
Commercial laboratory 
Other 
Two or more institution types 
 
145 
85 
59 
25 
34 
14 
19 
 
42.3 
24.8 
17.2 
7.3 
9.9 
4.1 
5.5 
Region 
Northeast 
Mid-Atlantic 
Southeast 
Southwest 
Midwest 
West 
Northwest 
Other 
 
50 
42 
43 
53 
94 
30 
16 
15 
 
14.6 
12.2 
12.5 
15.5 
27.4 
8.8 
4.7 
4.4 
Currently seeing patients 
Yes 
No 
 
298 
45 
 
86.9 
13.1 
Currently counseling about NIPT 
Yes 
No 
 
206 
137 
 
60.1 
39.9 
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Table 2         Awareness of NIPT’s ability to indicate maternal neoplasms, n (%) 
 Prenatal Non-Prenatal Total 
Source n = 168 n = 175 n = 343 
Professional conference, journal, discussion forum 96 (57.1) 104 (59.4) 200 (58.3) 
Colleague 31 (18.5)   35 (20.0)   66 (19.2) 
Personal experience 20 (11.9) 10 (5.7) 30 (8.7) 
Popular media 8 (4.8)   3 (1.7) 11 (3.2) 
I was not previously aware 7 (4.2) 10 (5.7) 17 (5.0) 
Other 5 (3.0)   7 (4.0) 12 (3.5) 
I do not recall 1 (0.6)   6 (3.4)   7 (2.0) 
 
Pre-test counseling for NIPT 
Genetic counselors who completed the Prenatal Arm ranked how frequently various 
pre-test counseling points were included when discussing NIPT for a routine indication such as 
for advanced maternal age by using a Likert scale ranging from “always” to “never.” Figure 1 
demonstrates the frequencies for each pre-test counseling point. Of note, counseling that NIPT 
results may indicate unexpected or rare conditions in the pregnancy or mother was “always” 
discussed only 12.5% of the time, with 44.6% “rarely” or “never” mentioning this possibility. 
Prenatal counselors who had personally experienced a case in which NIPT results indicated  
maternal neoplasms were more likely to include this statement in their pre-test counseling (p = 
0% 20% 40% 60% 80% 100%
Possible reasons for a false negative
Possibility of unexpected/rare results
Possible reasons for a false positive
NIPT may not yeild a result
cfDNA originates from the placenta
NIPT can evalute for fetal sex
Positive NIPT warrants diagnostic testing
Accuracy of NIPT
Possibility of false negatives/positives
Figure 1        Frequencies of pre-test counseling discussion points for NIPT
Always Mostly Sometimes Rarely Never
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0.028). There were no other statistical correlations found between inclusion of this statement 
and other measured variables. 
A majority (67.7%, 109/161) of counselors who completed the Prenatal Arm reported 
that their pre-test counseling had not changed since becoming aware of the possibility that 
NIPT could indicate maternal neoplasms, as illustrated in Table 3. 
 
 
 
 
 
 
Counselors were more likely to report that their pre-test counseling had changed if they 
had encountered this type of case in their own clinical experience (p < 0.001), or if they had 
more years of experience overall (p = 0.003). However, general awareness of NIPT’s neoplasm 
screening ability did not play a role in change of pre-test counseling (p = 0.154). Out of the 20 
Prenatal Arm counselors who reported having personal experience, 11 further elaborated on 
how their pre-test counseling has changed since this experience. Four stated that they will 
explicitly discuss cancer as a possibility in every pre-test counseling session for NIPT, while 3 
stated that they now vaguely allude to the possibility of detecting “maternal health factors.” 
Three participants in this subgroup said they treat it on a case-by-case basis, and one reported 
they no longer use an NIPT platform where this is a possibility. For the remaining 148 Prenatal 
Arm counselors who did not have personal experience with this indication, 71 (48.0%) 
participants chose to describe their changes, or lack of changes, to pre-test counseling, as 
illustrated in Table 4.  
Table 3           Perceived changes in pre-test counseling for NIPT 
Perceived change n*  % 
Yes, it has greatly changed 6  3.7 
Yes, it has slightly changed 46  28.6 
No, it has not changed 109  67.7 
*Six participants who were not previously aware were not instructed to answer 
this question (n = 161) 
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Table 4       Free responses:  perceived changes in pre-test counseling (n = 71) 
 
 
Yes, it has changed (n = 31) 
 
 
Inclusion of vague statement (n = 17, 54.8%) 
“I counsel that other chromosome changes may be identified that need further 
clarification, but I do not specifically counsel that changes may reflect a 
neoplasm/cancer.” 
 
Always discuss (n = 5, 16.1%) 
“I always, always, always incorporate this into my consent process now. I think it’s 
extremely important that this testing can reveal more about Mom than we were 
expecting, and I think it’s essential that the patient understands this.” 
 
Case by case basis (n = 4, 12.9%) 
“If the patient has a personal history/high risk of cancer or a strong family history of 
cancer, I discuss the possibility that NIPT can occasionally detect cancers. The 
information has not been incorporated into typical counseling sessions because of the 
rarity of this type of result and the lack of data available on likelihoods, outcomes, 
etc.” 
 
Added to consent form (n = 3, 9.7%) 
“We have added a short part to our verbal consent that states that some results may 
tell us information about the patient’s health and could require follow-up testing.” 
 
Other (n = 2, 6.5%) 
 
 
No, it has not changed (n = 40) 
 
 
Don’t discuss (n = 26, 65.0%) 
“Still a lot of unknowns at this point. As a practice, we have decided not to change 
things yet.” 
  
“With many types of prenatal genetic screening (ultrasound, traditional maternal 
serum screening, etc.) there is a possibility of incidentally obtaining information that 
suggests increased risk of a maternal or fetal health condition unrelated to the primary 
purpose of the screen. In my opinion, pre-test counseling would serve no useful 
purpose and could lead patients to mistakenly believe that one of the roles of NIPT is 
cancer screening.” 
 
Previously aware (n = 4, 10.0%) 
“I only started counseling patients after I learned of this.” 
 
Use different lab (n =3, 7.5%) 
“I do not counsel about uncovering possible maternal cancers because I am told by the 
lab whose test we use that their technology isn’t going to pick that up.” 
 
Other (n = 7, 17.5%) 
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Reporting preferences 
Participants who completed the Prenatal Arm were asked to state whether or not they 
would disclose NIPT results indicative of a maternal neoplasm to a patient or provider if results 
were not explicitly documented on the report – as was the current practice at the time of this 
survey – versus if they were clearly documented on the report. Of those who completed the 
Prenatal Arm, 76.8% (129/168) indicated that they would disclose this information to a patient 
even if it was not documented on the report. Twenty-one percent (36/168) indicated they were 
unsure if they would disclose, and 1.8% (3/168) reported they would not disclose this 
information in any capacity. One-hundred twenty six (75.0%) participants chose to provide 
reasons for why they would disclose this to a patient or not.  Commonly observed response 
themes and accompanying examples are illustrated in Table 5.  Conversely, almost all 
participants stated that they would disclose this to a patient if it were clearly documented on the 
test report (99.4%); one individual indicated that he or she was “unsure.” 
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Table 5       Free responses:  choice to disclose if results were not documented (n = 126) 
 
 
Yes, I would disclose (n = 116) 
 
 
Ethical principles (n = 55, 47.4%) 
“I likely would. I think it’s important to note that we don’t know how good the test is at 
identifying neoplasms/cancer, and that it might not be the reason we’re seeing what 
we’re seeing, but the patient has the right to know and investigate further.” 
 
“I feel it would be unethical not to inform them to give them the chance to be checked 
for malignancy.” 
 
Significant health implications (n = 35, 30.2%) 
“This has vital implications for the patient’s health and an appropriate work-up should 
be performed.” 
 
“I would rather subject the patient to possibly unnecessary worry and cancer 
screenings than have her pass away from a potentially treatable cancer (or have a 
more complex treatment course) if it had been found early because I mentioned it.” 
 
Consult with provider first (n = 10, 8.6%) 
“It would be discussed with the MFM first and we would decide how to best handle the 
situation together.” 
Other (n = 16, 13.8%) 
“I would likely think that yes, I would; but I imagine that as an office, we would need to 
make ourselves aware of the medical/legal aspects of informing a patient of an 
essentially undocumented result. I can’t imagine NOT saying something, but I don’t 
exactly know what I would say or what recommendations I would make.” 
 
“Case-by-case basis. I would want to talk with the lab first. I would also want to 
consider what could have made the data look that way – ie does the patient have 
fibroids that could cause concern for cancer on NIPT?” 
 
 
No, I would not disclose (n = 10) 
 
 
No data/not validated/no guidelines (n = 6, 60.0%) 
“I would have to discuss with my MFM team and our director first. Since there is no 
guideline, it’s like we are looking in the dark without a flashlight. Plus, insurance 
won’t cover the expensive MRI, CT, etc. based on an abnormal [NIPT] result because 
there is so little data. I don’t’ want my patient to get stuck with a huge bill only to find 
nothing and keep her up at night for the rest of her life.” 
 
“No. The testing has not been validated to test for maternal neoplasm and the data is 
sparse. There are no recommendations for following a patient in this scenario.” 
 
Other (n = 4, 40.0%) 
“Unless I have a report in writing from the performing lab, I have no basis to disclose 
an incidental finding to the patient.” 
 
“If I disclosed this information, then I am assuming personal liability for whether this 
information is correct or not.” 
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Participants of both arms were asked if they believe the potential benefits of NIPT’s 
neoplasm screening ability outweigh its potential risks both currently and in the future. They 
were also asked if NIPT companies should report non-validated findings, such as for 
neoplasms/cancer. Responses are recorded and discussed in the Attitudes section below. 
Counselors in the Prenatal Arm were more likely to disclose this information in the absence of 
documentation if they believed that both currently, and in the future, the benefits of NIPT’s 
ability to indicate maternal neoplasms outweigh the potential harms (p < 0.001 and p = 0.027, 
respectively). Counselors who were more likely to withhold this information believed that 
NIPT companies should not report non-validated findings (p < 0.001). There were no 
significant differences in choice to disclose between those who had personal experience 
counseling this type of case versus those who did not (p = 0.489).  
All participants (Prenatal and Non-Prenatal Arms) were asked for their opinion 
regarding the reporting of incidental findings of maternal neoplasms. A significant majority 
(69.1%) believed that findings should be discussed by a lab director as well as documented on 
the report.  A smaller number (12.5%) believed that findings should continue to be discussed 
by a lab director, but not documented on the report. Three percent of participants felt that 
findings should not be reported in any capacity, whereas 12.8% were unsure. For those who 
elaborated on their answers (n = 193), commonly observed response themes and accompanying 
examples are listed in Table 6. 
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Table 6      Free responses:  preferences for maternal neoplasm results reporting (n = 113) 
Documentation  
“Potentially clinically relevant findings shouldn’t be excluded from the report. Relying 
only on direct communication could result in miscommunication if multiple providers 
are involved (OB, MFM, primary care, etc.).” 
 
“It is extremely frustrating for legal and ethical reasons for findings to be disclosed to 
a medical provider and yet not included on the report.” 
Justification for referrals 
“Documentation of increased risk is important for insurance coverage regarding 
cancer screening.” 
 
“Labs should always be willing to document any reports they are providing. In 
addition, if insurance coverage of follow-up is ever an issue, documentation of an 
initial, initiating event would be pretty much essential.” 
Discussion 
“I feel like it should not be included on the report because NIPT is not designed to pick 
it up, and we do not yet know what the performance is like for detection of maternal 
cancer (PPV, follow-up recommendations ,etc.). However, I do feel that the lab 
director should ALWAYS call the ordering provider when these results are found, since 
the follow-up should be on a case-by-case basis.” 
 
“It depends on how reliable the results are – I see no issues in discussion with a GC 
(aside from the usual concerns about how much patients remember what we tell them, 
etc.), but inclusion on a report can sometimes lead providers to think ‘definitely’ when 
the scenario is ‘possible.’” 
Incidental findings are common 
“They are incidental findings, not exactly the same but similar to the ones we 
encounter with WES. These NIPT findings shouldn’t be ignored any more than the WES 
incidental findings. However, the ability to screen for them should be validated first 
and guidelines need to be established so GCs know where to refer patients once these 
abnormal results are reported.” 
 
“It is a medically actionable finding. It was not a part of the initial consent but 1) it 
should be, and 2) if a lung tumor is picked up by a lung x-ray for pneumonia, it is still 
reported.” 
Opt in or out 
“There should be an opt out option on the form for individuals to select whether or not 
they would like to receive any incidental findings.” 
Results should not be reported 
“Technically we consent for NIPT as a test that gives information about the baby, not 
the mom.” 
 
“NIPT has not been validated for this purpose and laboratories should not offer 
information that they cannot include on a report.” 
 
“I don’t think we have enough data, at this time, to know what percentage of double 
aneuploidies or aberrant results actually end up being diagnosed as maternal cancer. I 
feel that if more data emerges and shows that the majority of the time it is maternal 
neoplasm, then we can put it on the report without causing undue fear and anxiety. If it 
is a minority of cases, I don’t know if having that on a report would have some sort of 
potential insurance implications for that person as a ‘risk for cancer’ was diagnosed.” 
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Individuals who reported personal experience with this type of case were more likely to 
feel that results should be discussed AND documented (p = 0.024). Additionally, those who 
believed that both the current and future benefits of NIPT’s ability to indicate maternal 
neoplasms outweigh the harms were more likely to believe that findings should be discussed 
AND documented (p < 0.001 for both factors).  
All participants were asked who they believe should decide as to whether NIPT 
incidental findings of maternal neoplasms/cancer are reported (select all that apply). Responses 
are summarized in Figure 2. This was not influenced by the counselors’ area of practice, as 
those who reported practicing in a lab or industry setting were not more likely to feel that 
performing labs should be involved in this decision (p = 0.450).  
 
Counseling strategies 
A majority of counselors who completed the Prenatal Arm (51.8%) reported that they 
would feel either uncomfortable or very uncomfortable counseling this type of indication. 
Figure 2 Who should decide if NIPT neoplasm results are reported?  (n = 628) 
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Counselors were more likely to feel comfortable counseling these cases had they already 
encountered one in their personal experience (p < 0.001). Conversely, counselors were more 
likely to feel uncomfortable if they believed that the benefits of NIPT’s ability to indicate 
maternal neoplasms do not currently outweigh the harms (p < 0.001), and that NIPT companies 
should not report non-validated findings (p = 0.009).  
When asked what further recommendations, options, or referrals would be made when 
counseling a case for which NIPT results indicate a maternal neoplasm, counselors were asked 
to choose all that apply from several selections. Eighty-six percent of participants felt that more 
than one recommendation or referral was appropriate, with an average of 3 selections per 
participant. Twenty-five percent of participants indicated they were unsure about what 
recommendations or referrals they would make in this setting. The number of selections is 
depicted in Figure 3. Of note, “other” recommendations included offering whole-body MRIs or 
referrals to cancer genetic counselors. 
 
Figure 3 Recommendations/referrals (n = 528) 
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The subgroup who reported personal experience with this indication recommended 
equally diverse follow-ups, with a nine of the available eleven options being selected at least 
once (n = 79). Counselors in this subgroup were more likely to suggest a referral to oncology (p 
= 0.004), recommend performing a traditional screen (p = 0.044), or an invasive test (p = 
0.001). However, counselors with personal experience were less likely to select “unsure” as an 
option (p = 0.025). There were no significant differences for the other selections. 
Counselors were asked to select from any of the available options summarized in Figure 
4 that they felt would better help prepare them for counseling a patient with this indication. A 
majority (91.2%, 315/343) felt that more than one resource was needed, with an average of 3 
selections per participant.   
 
Attitudes 
As previously stated, participants of both arms were asked if they believed that the 
potential benefits of NIPT’s ability to screen for neoplasms/cancer outweigh its potential 
Figure 4 Resources needed by counselors (n = 1,133)  
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harms, both currently and in the future. Additionally, counselors were asked their opinion as to 
whether NIPT companies should report non-validated findings, such as for neoplasms or 
cancer. Findings are summarized in Figure 5a and Figure 5b, respectively.  
 
Figure 5a:    Attitudes regarding NIPT’s ability to indicate maternal neoplasms (n = 343) 
Figure 5b:    Attitudes regarding NIPT’s ability to indicate maternal neoplasms (n = 343) 
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A majority of counselors from both arms either agreed or strongly agreed that the 
benefits of NIPT’s ability to indicate maternal neoplasms currently outweigh its harms. 
Counselors who reported personal experience with an NIPT neoplasm case were more likely to 
agree that benefits outweigh the harms both currently and in the future (p = 0.026 and p = 
0.043, respectively).  There was a significant positive shift of responses on the Likert scale 
when asked about the potential future benefits; counselors were more likely to express 
agreement in this scenario than in the former (p < 0.001).  
About half of all counselors felt that despite these feelings not being validated, NIPT 
labs should still report these to providers. Lab and pediatric genetic counselors were less likely 
to agree (p = 0.083 and 0.575, respectively), whereas counselors who practiced in prenatal and 
cancer settings were more likely to agree with this statement (p = 0.001 and 0.004, 
respectively).  
DISCUSSION 
Three hundred forty-three genetic counselors were surveyed on their awareness, 
preferences, and attitudes regarding the ability of NIPT to indicate maternal neoplasms. Despite 
the rarity of this indication, our study shows that the majority (95%) of genetic counselors were 
aware NIPT results may indicate maternal neoplasms at the time they were surveyed. This 
awareness is most likely attributed to the fact that data regarding NIPT’s ability to detect 
maternal malignancy was presented at a national genetics conference (ACMG) [14, 15], as well 
as published by Bianchi et al. [19] shortly prior to the survey distribution. This is corroborated 
by the fact that the majority of participants (58.3%, 200/343) stated that they learned of NIPT’s 
ability to indicate maternal neoplasms through a professional conference, peer-reviewed 
journal, or discussion forum. However, when asked about “maternal neoplasms,” a specific 
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delineation was not made in this survey between malignant/cancerous neoplasms and benign 
neoplasms such as fibroids. The world “fibroid” was only mentioned by two participants in the 
study, while different variations of “not necessarily cancer” were mentioned 13 times. 
However, phrases such as “significant health complications,” “life-saving,” or “cancer” were 
mentioned 60 times. Therefore, a conclusion cannot be made as to whether respondents were 
aware that NIPT can raise concern for BOTH benign and malignant neoplasms, as opposed to 
just malignancy.  
Although awareness of NIPT’s ability to indicate maternal cancers was high among all 
counselors, and recommendations have been proposed to include the discussion of the 
possibility of “maternal or fetal incidental findings” in pre-test counseling [24], only 29% of 
prenatal counselors who discuss NIPT report routinely including this statement in their pre-test 
counseling, with 44.6% reporting they “rarely” or “never” discuss it. Simply becoming aware 
of NIPT’s neoplasm screening ability did not seem to introduce a significant change to 
counselors’ pre-test counseling for NIPT (p = 0.154). Rather, a change to pre-test counseling 
was observed when counselors instead had encountered this indication first-hand (p < 0.001). 
This suggests that these experiences have greatly influenced the way in which these counselors 
have chosen to approach pre-test counseling for NIPT.  
However, those who have made changes to their pre-test counseling cite inconsistent 
methods for communicating this possibility to patients. Most counselors (47.6%, 20/42) said 
they now include a vague statement about the possibility of uncovering “unexpected results,” 
but some (21.4%, 9/42) will always explicitly mention that neoplasms or cancer can confound 
results. Others (7/42, 16.7%) treat the discussion of this on a case-by-case basis, including this 
only for patients who have a personal history of caner, are “information-seeking,” or “highly 
anxious.” Those who have decided not to discuss this possibility in the pre-test setting cite 
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barriers such as a lack of validated data or guidelines for patient management. Only 10% (4/41) 
of respondents who elaborated on their choice to not change their pre-test counseling stated that 
they do not order NIPT through a lab that performs testing via MPSS. This data shows that 
despite large awareness amongst counselors, the discussion of the possibility of “maternal or 
fetal incidental findings” in pre-test counseling is not routinely being done even when testing is 
being ordered through labs that can indicate this finding, bringing into question if true informed 
consent is being obtained at the time of pre-test counseling.  
While the possibility of unexpected or rare results is not always addressed in pre-test 
counseling, 76.8% of the prenatal counselors surveyed reported that they would disclose results 
suspicious for maternal neoplasms to a patient, even if not clearly documented on the test 
report. This is despite the fact that approximately half of counselors reported they would feel 
“uncomfortable” or “very uncomfortable” counseling this type of indication. Counselors who 
support disclosure of results largely cited an ethical obligation to disclose results that may have 
significant health implications for their patient. Therefore, it appears that many counselors are 
comfortable stepping outside of their comfort zone if they perceive a benefit to their patient.  
Additionally, 69.1% of counselors across specialties felt that NIPT results indicative of 
maternal neoplasms should be both documented on the test report and discussed by the lab 
director in order to better understand the implications of the results and to justify further 
workup. Many individuals alluded to how this situation is not much different than incidental 
findings being uncovered with other genetic tests. As one participant stated, “They are 
incidental findings, not exactly the same but similar to the ones we encounter with [Whole 
Exome Sequencing]. These NIPT findings shouldn’t be ignored any more than the WES 
incidental findings.” 
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Conversely, counselors who did not support disclosure of these results, and who did not 
believe these results should be reported or documented, consistently cited the overall lack of 
data and guidelines as barriers. One participant summarized it as “looking in the dark without a 
flashlight.” Given the paucity of available information about the sensitivity, specificity, or 
positive predictive value of NIPT’s ability to screen for maternal neoplasms, it is not 
unreasonable for counselors to have these reservations. Furthermore, unlike medically 
actionable incidental findings uncovered from other medical tests, the need for medical action 
following abnormal NIPT results indicating maternal neoplasm has not yet been clearly 
defined.  It is also uncertain what, if any, appropriate clinical evaluation or follow-up might be 
in these situations. This was further evidenced by the wide variation in recommendations or 
referrals that were suggested by the surveyed group when counseling a case for which NIPT 
results indicate maternal neoplasm. A majority (86%) would recommend more than one 
referral, and the most common selection made was for a referral to oncology. However, as 
Bettegowda [6] and Bianchi [19] found, it is possible that the neoplasm generating cfDNA is 
not yet to a stage where it would be detected by standard imaging. On average, detection of 
malignancy occurred approximately 5 months (range:  3 weeks – 39 weeks) after having an 
abnormal NIPT result in Bianchi’s cohort [19]. Additionally, the neoplasm may not even be 
malignant and require cancer treatment, as is the case for uterine fibroids. Some counselors in 
this cohort as well as in prior literature [26] suggested that whole-body MRI’s be offered to 
these patients. But without documentation of NIPT results justifying this workup, it is unlikely 
that insurance companies will cover these tests, some of which are contraindicated during 
pregnancy. This is without considering the fact that, as of April 2016, whole-body MRIs do not 
yet exist as a CPT code and are not recognized as a billable test by insurance companies [27]. 
And since not all malignancies are immediately detected following NIPT results, the timing and 
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duration of performing this workup is unclear. These frustrations were frequently cited by 
counselors in this cohort.  
Despite all of these limitations, 44% (152/343) of all counselors surveyed believed that 
the benefits of NIPT’s ability to indicate maternal neoplasms outweigh its potential harms. This 
held particularly true for counselors who had personal experience with this indication (p = 
0.026). Additionally, counselors who practiced in prenatal or cancer settings were more likely 
to agree that NIPT laboratories should report non-validated data such as neoplasms/cancer (p = 
0.001 and p = 0.004, respectively). This implies that those counselors who encountered this 
indication first-hand may be more likely to appreciate its utility or have directly observed its 
value, despite its clear limitations. It also implies that prenatal and cancer counselors appreciate 
knowing more information from the laboratories even when limited.  
As the number of high-risk and low-risk women undergoing NIPT expands, it is not 
unreasonable to predict that results indicating maternal neoplasms may become more common. 
Expanded non-invasive methods evaluating genome-wide copy number variants may also 
capture more women with neoplasms of altered chromosomes not routinely analyzed with 
traditional NIPT (21, 18, 13, X, and Y). While it can be assumed that the majority of the burden 
of pre-test and particularly post-test counseling will fall on prenatal counselors, further workup 
may call upon involvement and collaboration between counselors from multiple specialties. 
Ultimately, NIPT was not designed to detect maternal neoplasms, or maternal genetic 
aberrations in general. However, this is a real possibility of the testing and a majority (80.2%) 
of counselors believe that the benefits will outweigh the harms in the future. Currently 
however, the inconsistencies observed in pre-test counseling, recommendations for patient 
management, and reporting preferences demonstrate a need for national or institutional 
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guidelines to establish a standard by which counselors can base their counseling. Ninety-one 
percent of counselors in this cohort across all specialties ultimately affirmed that guidelines 
were necessary to better prepare for these cases both pre- and post- test, and to make 
appropriate recommendations. Additional counselors make a call for more literature and case 
reports, as well as discussion and presentations through various platforms, including national 
conferences.  
Limitations 
This study could possibly reflect a skewed population, biased by ascertainment, in 
which counselors who were not familiar with this topic may have been dissuaded to participate 
in the survey. Additionally, as previously discussed, this survey was distributed shortly 
following the annual ACMG conference in 2015, in which this topic was discussed. Those who 
attended this conference could have thus been more aware and educated about this possibility, 
and more inclined to participate.  
Additional limitations included a study design that was not based upon validated 
measures. The subgroup that represented counselors with personal experience with a case in 
which maternal neoplasms were indicated with NIPT was derived from a question aimed to 
assess awareness. This group represented those who selected “I have encountered a case like 
this in my personal experience” when asked, “How did you first learn of this possibility?” This 
may have inadvertently excluded those who have encountered such a case, but had learned 
about this possibility prior to that event. Therefore, this sample (n = 30) may not encompass 
everyone who experienced a case like this first-hand. Further limitations to study design 
included the exclusion of an explicit definition of “neoplasm,” as previously discussed.  
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Future Directions 
As evidenced by genetic counselors’ desire for more information, the next most 
appropriate step would be to publish more data regarding NIPT’s neoplasm screening ability. 
Due to the rarity of these events, collaboration amongst researchers, clinicians, and laboratories 
is needed.  
As these results have equal implications for OB/GYNs who might encounter them in 
clinical practice either with or without access to a genetic counselor, future research might 
explore similar factors regarding the awareness, preferences, and attitudes of OB/GYNs. 
Governing bodies that produce guidelines such as the American College of Obstetrics and 
Gynecology and the National Society of Genetic Counselors may be prompted to create 
recommendations for patient counseling and management. 
Additionally, exploring patient preferences may provide an interesting view of how to 
move forward with developing or later, adapting guidelines. This could include an examination 
of the psychosocial effects of receiving incidental findings with such a range of implications, 
from a fibroid to a cancer that cannot be detected with imaging.  
CONCLUSION 
 While NIPT results suggestive of maternal neoplasms are thought to be rare, they 
present a challenge for clinicians since little direction is currently available to help guide 
patient counseling and management. These results have the potential to indicate significant 
health implications for the patient, and the majority of counselors in this study felt the 
information was beneficial. However, a majority do not feel properly equipped to counsel this 
indication due to a lack of data. This study demonstrates a need for collaboration amongst 
28 
 
clinicians, researchers, and laboratories to publish data, and prompts institutional or national 
governing bodies to create guidelines from which clinicians can base their practice. 
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APPENDIX 
Survey Questions 
1. How many total years of experience do you have as a genetic counselor? 
a. 0 – 5 years 
b. 6 – 10 years 
c. 11 – 15 years 
d. 16 – 20 years 
e. > 20 years 
2. How many total years of experience do you have in your current specialty? 
a. 0 – 5 years 
b. 6 – 10 years 
c. 11 – 15 years 
d. 16 – 20 years 
e. > 20 years 
3. In what type of institution do you currently work? [select all that apply] 
a. University medical center 
b. Private hospital/medical facility 
c. Public hospital/medical facility 
d. Physician’s private practice 
e. Commercial laboratory 
f. Other: ___________________ 
4. In what region do you currently work? 
a. Northeast:  CT, MA, ME, NH, NY, RI, VT 
b. Mid-Atlantic:  DE, MD, NJ, PA, VA, WV 
c. Southeast:  AK, AL, FL, GA, LA, MS, NC, SC, TN 
d. Southwest:  AZ, CO, NM, OK, TX, UT 
e. Midwest:  IA, IL, IN, KA, KY, MI, MN, MO, NE, ND, OH, SD, WI 
f. West:  AK, CA, HI, NV 
g. Northwest:  ID, MT, OR, WA, WY 
h. Other: ___________________ 
5. Do you currently see patients: 
a. Yes 
b. No 
6. Do you currently counsel patients about non-invasive prenatal testing OR discuss non-
invasive prenatal testing with medical providers? 
a. Yes 
b. No 
7. What is your current genetic counseling specialty? [select all that apply] 
a. Prenatal 
b. Cancer 
c. Laboratory/Industry 
d. Pediatrics/Medical Genetics 
e. Other: ___________________ 
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PRENATAL ARM 
8. For the below section, assume you are counseling a patient for a routine indication for non-
invasive prenatal testing (NIPT), such as advanced maternal age (AMA), positive quad 
screen, etc.  Please select the frequency for which you discuss the following during PRE-
TEST COUNSELING for NIPT: 
 Always Most of the time Sometimes Rarely Never 
NIPT can evaluate for fetal sex      
Accuracy of NIPT      
NIPT may not yield a result      
Cell-free DNA originates from the 
placenta 
     
Either false negatives or false 
positives may occur 
     
Confirmation of a positive NIPT 
result warrants further diagnostic 
testing, such as CVS or 
amniocentesis 
     
Possible reasons for a false 
positive result  
     
Possible reasons for a false 
negative result 
     
Results may indicate unexpected 
or rare conditions in pregnancy or 
mother 
     
 
9. Are you aware that NIPT results have prompted concern for and/or have led to the 
diagnosis of maternal neoplasms/cancers in pregnant women? If so, how did you first learn 
that NIPT could indicate maternal neoplasms? 
a. I was not previously aware that NIPT could indicate maternal neoplasms/cancer 
b. I have encountered a case like this in my own clinical experience 
c. From a colleague 
d. A professional conference, peer-reviewed journal, or discussion forum 
e. Popular media, such as an online news article 
f. I do not recall 
g. Other: ___________________ 
 
10.   Since becoming aware of NIPT’s ability to indicate maternal neoplasms/cancer, has your 
NIPT PRE-TEST counseling changed? 
a. Yes, it has greatly changed 
b. Yes, it has slightly changed 
c. No, it has not changed 
 
11.   Please feel free to elaborate. [free response] 
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Pregnant patients with abnormal NIPT results indicative of maternal neoplasms/cancers with 
chromosomal abnormalities originating from the tumor have been reported. As of June 2015, 
concerns for neoplasms/cancer are not documented on the NIPT report, but are verbally 
discussed by laboratory directors, or are reported as multiple aneuploidies in some cases.  
 
12.  If an NIPT laboratory informed you of a concerning NIPT result indicative of a possible 
maternal neoplasm/cancer, but this information was NOT included on the NIPT report, 
would you disclose this information to your patient? 
a. Yes 
b. No 
c. Unsure 
 
13.   Why or why not? [free response] 
 
14.   If an NIPT laboratory informed you of a concerning NIPT result indicative of a possible 
maternal neoplasm/cancer, but this information WAS included on the NIPT report, would 
you disclose this information to your patient? 
a. Yes 
b. No 
c. Unsure 
 
15.   Why or why not? [free response] 
 
16.   What further recommendations, options, or referrals would you make, if any? [select all 
that apply] 
a. No further recommendations 
b. Referral to oncology  
c. Referral back to OB/GYN or MFM 
d. Referral to PCP 
e. Referral to medical geneticist 
f. Repeat NIPT 
g. Perform traditional screening test (FTS, quad) 
h. Invasive testing (CVS, amniocentesis) 
i. Ultrasound 
j. Unsure 
k. Other: ___________________ 
 
17.   How comfortable would you feel counseling a patient about NIPT results indicating 
maternal neoplasms/cancer? 
a. Very comfortable 
b. Comfortable 
c. Neutral 
d. Uncomfortable 
e. Very uncomfortable 
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18.   How would you prefer for incidental findings of possible maternal neoplasms/cancer to be 
reported? 
a. Findings should NOT be reported 
b. Findings should be discussed by a lab director or lab genetic counselor AND 
included on the report 
c. Findings should be discussed by a lab director or lab genetic counselor but NOT 
included on the report 
d. I do not have a preference 
e. Unsure 
f. Other: __________________ 
 
19.   Why or why not? [free response] 
 
20.   Who should be making the decision as to whether NIPT incidental findings of possible 
maternal neoplasms/cancer are reported? [select all that apply] 
a. Performing labs 
b. Ordering clinicians 
c. Patients 
d. Institutional or national guidelines 
e. Unsure 
f. Other: __________________ 
 
21.   What information do you feel would help better prepare you for these cases? 
a. Institutional or national guidelines for reporting, management, and consent 
b. Peer-reviewed publications or published case reports 
c. More presentations or discussions regarding these cases at national conferences such 
as NSGC, ACMG, ACOG, etc. 
d. Laboratory-provided data on sensitivity and specificity for neoplasm screening 
e. Unsure 
f. Other: __________________ 
Please indicate your level of agreement with the following statements: 
22.   At this time, I believe the potential benefits of NIPT’s ability to screen for 
neoplasms/cancer outweigh the potential for harm 
a. Strongly Agree 
b. Agree 
c. Neutral 
d. Disagree 
e. Strongly Disagree 
23.   In the future, I believe the potential benefits of NIPT’s ability to screen for 
neoplasms/cancer outweigh the potential for harm 
a. Strongly Agree 
b. Agree 
c. Neutral 
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d. Disagree  
e. Strongly Disagree 
 
24.   NIPT companies should not report non-validated findings, such as maternal 
neoplasms/cancer 
a. Strongly Agree 
b. Agree 
c. Neutral 
d. Disagree 
e. Strongly Disagree 
NON-PRENATAL ARM 
NIPT (noninvasive prenatal testing) is a blood test that analyzes cell-free fetal DNA in maternal 
circulation. The test is offered to women during pregnancy and is primarily used to screen for 
fetal aneuploidies such as trisomy 21, trisomy 18, and trisomy 13. Pregnant patients with 
abnormal NIPT results indicative of maternal neoplasms or cancers with chromosomal 
abnormalities originating from the tumor have been reported. As of June 2015, concerns for 
neoplasms/cancers are not documented on NIPT reports, but are verbally reported by laboratory 
directors, or are reported as multiple aneuploidies in some cases. 
8. Were you previously aware that NIPT results have prompted concern for and/or have led to 
the diagnosis of maternal neoplasms/cancers in pregnant women? If so, how did you first 
learn that NIPT could indicate maternal neoplasms? 
a. I was not previously aware that NIPT could indicate maternal neoplasms/cancer 
b. I have encountered a case like this in my own clinical experience 
c. From a colleague 
d. A professional conference, peer-reviewed journal, or discussion forum 
e. Popular media, such as an online news article 
f. I do not recall 
g. Other: ___________________ 
 
9. How would you prefer for incidental findings of possible maternal neoplasms/cancer to be 
reported? 
a. Findings should NOT be reported 
b. Findings should be discussed by a lab director or lab genetic counselor AND 
included on the report 
c. Findings should be discussed by a lab director or lab genetic counselor but NOT 
included on the report 
d. I do not have a preference 
e. Unsure 
f. Other: __________________ 
 
10.   Why or why not? [free response] 
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11.   Who should be making the decision as to whether NIPT incidental findings of possible 
maternal neoplasms/cancer are reported? [select all that apply] 
a. Performing labs 
b. Ordering clinicians 
c. Patients 
d. Institutional or national guidelines 
e. Unsure 
f. Other: __________________ 
 
12.   What information do you feel would help better prepare you for these cases? 
a. Institutional or national guidelines for reporting, management, and consent 
b. Peer-reviewed publications or published case reports 
c. More presentations or discussions regarding these cases at national conferences such 
as NSGC, ACMG, ACOG, etc. 
d. Laboratory-provided data on sensitivity and specificity for neoplasm screening 
e. Unsure 
f. Other: __________________ 
 
Please indicate your level of agreement with the following statements: 
13. At this time, I believe the potential benefits of NIPT’s ability to screen for 
neoplasms/cancer outweigh the potential for harm 
a. Strongly Agree 
b. Agree 
c. Neutral 
d. Disagree 
e. Strongly Disagree 
 
14.   In the future, I believe the potential benefits of NIPT’s ability to screen for 
neoplasms/cancer outweigh the potential for harm 
a. Strongly Agree 
b. Agree 
c. Neutral 
d. Disagree  
e. Strongly Disagree 
 
15.   NIPT companies should not report non-validated findings, such as maternal 
neoplasms/cancer 
a. Strongly Agree 
b. Agree 
c. Neutral 
d. Disagree 
e. Strongly Disagree 
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